Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 70.35
+4.80 (7.32%)
Aug 20, 2026, 4:09 PM HKT
Shanghai Henlius Biotech Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 38,235 | 31,006 | 12,881 | 7,555 | 6,957 | 11,984 | |
Market Cap Growth | -16.20% | 140.72% | 70.50% | 8.59% | -41.95% | -53.03% |
Enterprise Value | 41,299 | 33,962 | 16,522 | 11,112 | 10,233 | 13,635 |
Last Close Price | 70.35 | 57.05 | 23.70 | 13.90 | 12.80 | 22.05 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 41.87 | 33.69 | 14.75 | 12.56 | - | - |
Forward PE | 26.47 | 27.52 | 15.91 | 12.55 | - | - |
PS Ratio | 5.15 | 4.18 | 2.11 | 1.27 | 1.91 | 5.80 |
PB Ratio | 8.68 | 7.04 | 4.02 | 3.13 | 3.76 | 4.25 |
P/TBV Ratio | 79.21 | 64.23 | - | - | - | 25.87 |
P/FCF Ratio | 34.56 | 28.02 | 11.23 | 11.94 | 15.51 | - |
P/OCF Ratio | 26.32 | 21.34 | 9.75 | 6.54 | 6.27 | 108.01 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.57 | 4.58 | 2.71 | 1.87 | 2.82 | 6.60 |
EV/EBITDA Ratio | 29.97 | 26.24 | 13.36 | 10.82 | - | - |
EV/EBIT Ratio | 45.42 | 37.35 | 17.92 | 15.45 | - | - |
EV/FCF Ratio | 37.33 | 30.70 | 14.40 | 17.57 | 22.82 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.91 | 0.91 | 1.21 | 1.87 | 2.25 | 1.14 |
Debt / EBITDA Ratio | 2.91 | 2.91 | 2.96 | 4.07 | - | - |
Debt / FCF Ratio | 3.62 | 3.62 | 3.39 | 7.13 | 9.27 | - |
Net Debt / Equity Ratio | 0.70 | 0.70 | 0.94 | 1.41 | 1.81 | 0.82 |
Net Debt / EBITDA Ratio | 2.37 | 2.37 | 2.44 | 3.31 | -7.06 | -3.63 |
Net Debt / FCF Ratio | 2.77 | 2.77 | 2.63 | 5.37 | 7.48 | -5.08 |
Asset Turnover | 0.58 | 0.58 | 0.56 | 0.57 | 0.40 | 0.25 |
Inventory Turnover | 2.51 | 2.51 | 2.07 | 1.95 | 1.44 | 1.44 |
Quick Ratio | 0.54 | 0.54 | 0.34 | 0.34 | 0.27 | 0.35 |
Current Ratio | 0.71 | 0.71 | 0.50 | 0.53 | 0.44 | 0.56 |
Return on Equity (ROE) | 23.72% | 23.72% | 31.52% | 28.52% | -35.35% | -35.81% |
Return on Assets (ROA) | 4.45% | 4.45% | 5.28% | 4.33% | -4.88% | -6.11% |
Return on Invested Capital (ROIC) | 12.17% | 13.01% | 15.11% | 12.67% | -14.32% | -16.48% |
Return on Capital Employed (ROCE) | 11.00% | 11.00% | 15.60% | 13.50% | -16.00% | -15.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.41% | 2.97% | 6.78% | 7.96% | -11.30% | -10.08% |
FCF Yield | 2.89% | 3.57% | 8.91% | 8.37% | 6.45% | -3.79% |
Buyback Yield / Dilution | -0.45% | -0.45% | -0.02% | -0.25% | -0.59% | -1.75% |